Dr. Shawn Leung is the scientific founder and CEO of SinoMab. He has had over 20 years of experience in the biotechnology industry and is proficient in the field of therapeutic antibody development. Prior to founding SinoMab, Dr. Leung had served as the Managing Director of the Hong Kong Institute of Biotechnology, and as the Executive Director, Biology Research, of Immunomedics, Inc., of New Jersey, USA. Dr. Leung is an inventor on over 20 patents and the author of more than 70 publications (Nature, Journal of Immunology, Nucleic Acid Research, Cancer Research, Clinical Cancer Research, etc.). His works and contributions in the field of therapeutic antibodies are highly regarded in China, and he is amongst the first non-residents in China obtaining approval as the Project Leader in the 863 program for the development of novel antibody based therapy for liver cancer. Dr. Leung received his D.Phil. in Molecular Biology from Oxford University and was a Howard-Hughes Medical Research fellow at Yale University. Dr. Leung holds various adjunct positions in different academic institutions, including the Biochemistry Department of CUHK, the Third Military Medical University in Chongqing, and the Fourth Military Medical University in Xian.